Sanofi OBS 17445

The Sanofi OBS17445 SAVANT study is a non-interventional, longitudinal safety study collecting data in patients with Pompe disease who are receiving enzyme replacement therapy (ERT) with avalglucosidase alfa as standard of care (SOC).

Specifically, this study wants to understand and characterize an important potential risk: infusion-associated reactions (IARs). By collecting data in this real-world, non-interventional setting, the study hopes to provide a detailed picture of the safety profile of avalglucosidase alfa in treating Pompe disease.

Enrollment Contact:
Lupita Rodriguez
(602) 406-6641
Fulton.Research@DignityHealth.org